Sunday, 20 September 2026European Markets

LUMIBIRD And TUBIZE-FIN Have A High Dividend Yield And Return On Equity In The Healthcare Sector.

Loading stream...

(vianews) - lumibird (lbird.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.

financial asset price forward dividend yield return on equity
lumibird (lbird.pa) €14.60 1.25% 5.68%
tubize-fin (tub.br) €85.60 0.97% 4.93%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. lumibird (lbird.pa)

1.25% forward dividend yield and 5.68% return on equity

lumibird sa designs, manufactures, and sells various lasers for the scientific, industrial, and medical applications worldwide. it operates in two segments, photonics and medical. the company offers solid-state and diode lasers, fiber lasers, fiber lasers/amplifiers and components, laser rangefinder and lidar wind doppler lidar, medical and ophthalmological equipment. its products are used in various applications, such as industrial and scientific, defense and space, and lidar sensors. the company was incorporated in 1970 and is headquartered in lannion, france.

earnings per share

as for profitability, lumibird has a trailing twelve months eps of €0.47.

pe ratio

lumibird has a trailing twelve months price to earnings ratio of 31.06. meaning, the purchaser of the share is investing €31.06 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.68%.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on jan 1, 1970, the estimated forward annual dividend yield is 1.25%.

volatility

lumibird's last week, last month's, and last quarter's current intraday variation average was a negative 2.87%, a positive 0.80%, and a positive 2.07%.

lumibird's highest amplitude of average volatility was 2.87% (last week), 2.06% (last month), and 2.07% (last quarter).

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, lumibird's stock is considered to be overbought (>=80).

more news about lumibird.

2. tubize-fin (tub.br)

0.97% forward dividend yield and 4.93% return on equity

financière de tubize sa operates as a mono holding company whose sole investment is a stake in ucb which is a biopharma company in belgium. the company is based in brussels, belgium.

earnings per share

as for profitability, tubize-fin has a trailing twelve months eps of €1.99.

pe ratio

tubize-fin has a trailing twelve months price to earnings ratio of 43.02. meaning, the purchaser of the share is investing €43.02 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.93%.

more news about tubize-fin.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com